Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions
Related Party Transactions	17. Related Party Transactions Transactions with Juventas. On July 1, 2019 the Company entered into a one-year equipment lease with Juventas, which is classified as an operating lease. Transactions with Juventas are considered to be related party transactions as the Company’s Chairman and CEO is the chairman and one of the founding shareholders of Juventas. The lease was renewed for another year in July 2020 and in June 2021. The lease income were RMB 155,000 ($23,000) and RMB 240,000 ($37,000), respectively, for the three months ended June 30, 2022 and 2021. The lease income were RMB 393,000 ($60,000) and RMB 480,000 ($73,000), respectively, for the six months ended June 30, 2022 and 2021. In June 2022, the Company and Juventas entered into a lab equipment transfer contract, pursuant to which the previous leasing agreement was terminated and the Company transferred the equipment to Juventas. Total consideration for the transfer was RMB 900,000 ($138,000) in cash. March 2021 Underwritten Public Offering Transactions. On March 24, 2021, the Company closed an underwritten public offering of 15,853,658 shares of the Company’s Common Stock (not adjusted to reflect the Reverse Stock Split, the “Offering”) at a price to the public of $2.05 per share. The gross proceeds to CASI from the Offering were $32.5 million before deducting the underwriting discounts and commissions and offering expenses payable by CASI. ETP BioHealth III Fund LP (“ETP BioHealth”), in which CASI’s Chairman and CEO is the founder and managing partner of ETP BioHealth’s general partner (Emerging Technology Partners, LLC (“ETP”), purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in the Offering. ETP BioHealth purchased 3,000,000 (not adjusted to reflect the Reverse Stock Split) shares at the public offering price of $2.05 per share for a total of $6.15 million.

Related Party Transactions

6 Months Ended

Jun. 30, 2022

17. Related Party Transactions

Transactions with Juventas.

On July 1, 2019 the Company entered into a one-year equipment lease with Juventas, which is classified as an operating lease. Transactions with Juventas are considered to be related party transactions as the Company’s Chairman and CEO is the chairman and

one of the founding shareholders of Juventas. The lease was renewed for another year in July 2020 and in June 2021. The lease income were RMB 155,000 ($23,000) and RMB 240,000 ($37,000), respectively, for the three months ended June 30, 2022 and 2021. The lease income were RMB 393,000 ($60,000) and RMB 480,000 ($73,000), respectively, for the six months ended June 30, 2022 and 2021.

In June 2022, the Company and Juventas entered into a lab equipment transfer contract, pursuant to which the previous leasing agreement was terminated and the Company transferred the equipment to Juventas. Total consideration for the transfer was RMB 900,000 ($138,000) in cash.

March 2021 Underwritten Public Offering Transactions.

On March 24, 2021, the Company closed an underwritten public offering of 15,853,658 shares of the Company’s Common Stock (not adjusted to reflect the Reverse Stock Split, the “Offering”) at a price to the public of $2.05 per share. The gross proceeds to CASI from the Offering were $32.5 million before deducting the underwriting discounts and commissions and offering expenses payable by CASI.

ETP BioHealth III Fund LP (“ETP BioHealth”), in which CASI’s Chairman and CEO is the founder and managing partner of ETP BioHealth’s general partner (Emerging Technology Partners, LLC (“ETP”), purchased shares of common stock in the Offering at the public offering price and on the same terms as the other purchasers in the Offering. ETP BioHealth purchased 3,000,000 (not adjusted to reflect the Reverse Stock Split) shares at the public offering price of $2.05 per share for a total of $6.15 million.